Pathophysiology of Hypertensive Heart Disease

Cuspidi, Cesare; Sala, Carla; Tadić, Marijana

doi:10.1007/978-3-319-93320-7_10

Cited by 1 publication

(2 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These changes are grouped under the term “target organ damage” or “hypertension-mediated organ damage.” Heart damage in hypertension has been defined by leading cardiologists in European Union and the United States as “hypertensive heart disease (HHD)” ( 3 – 5 ). Additionally, early manifestation of HHD is left ventricular (LV) hypertrophy ( 3 , 4 ). Focusing on the HHD it is important to note that chronically increased LV workload in hypertensive patients can result in LV hypertrophy, impaired LV relaxation, development of LV diastolic dysfunction, left atrial enlargement, an increased risk of arrhythmias, especially atrial fibrillation, and an increased risk of heart failure with preserved ejection fraction and heart failure with reduced ejection fraction ( 1 , 3 , 4 ).…”

Section: Introductionmentioning

confidence: 99%

“…These changes are grouped under the term "target organ damage" or "hypertensionmediated organ damage." Heart damage in hypertension has been defined by leading cardiologists in European Union and the United States as "hypertensive heart disease (HHD)" (3)(4)(5). Additionally, early manifestation of HHD is left ventricular (LV) hypertrophy (3,4).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Circulating microRNA-133a in Patients With Arterial Hypertension, Hypertensive Heart Disease, and Left Ventricular Diastolic Dysfunction

Koval

Snihurska

Yushko

et al. 2020

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Aim: The aim of the work was to study the circulating microRNA-133a levels in blood plasma of patients with arterial hypertension (AH), hypertensive heart disease (HHD), and left ventricular (LV) diastolic dysfunction (DD). Materials and Methods: A total of 48 patients with grade 2–3 AH and HHD at the age of 52.23 ± 7.26 (23 patients had LV DD [main group] and 25 patients had normal LV diastolic function [comparison group]) and 21 practically healthy individuals of comparable gender and age were examined. Diagnosis of AH and HHD was carried out according to the 2018 ESC/ESH recommendations. LV DD was determined according to the 2016 ASE/EACVI recommendations. Plasma microRNA-133a level was obtained by polymerase chain reaction using the CFX96 Touch System (BioRad), ≪TaqMan microRNA Assay≫ and ≪TaqMan® Universal PCR Master Mix≫ reagent kits (Thermo Fisher Scientific, USA). Results: We have found that in patients from the main and comparison groups plasma microRNA-133a levels were significantly lower than in practically healthy individuals (0.094 [0.067, 0.147]) and (0.182 [0.102, 0.301]) vs. (0.382 [0.198,0.474]), p = 0.002 and p = 0.04, respectively. In all this among patients with AH, HHD, and LV DD, plasma microRNA-133a levels were significantly lower than in patients with AH, HHD, and normal diastolic function ( p = 0.03). In the main and comparison groups there was a statistically significant negative relationship between plasma microRNA-133a level and left ventricular mass index (LVMI) ( R = −0.40, p = 0.003 and R = −0.35, p = 0.04, respectively). Conclusions: The findings suggest the significant role of decreased microRNA-133a levels in blood plasma of patients with AH in the pathogenesis and development of both HHD and LV DD.

show abstract